Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Decline in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX) saw a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 65,085 shares, a decrease of 40.0% from the May 14th total of 108,418 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily volume of 44,667 shares, the short-interest ratio is currently 1.5 days.

Dogwood Therapeutics Price Performance

NASDAQ:DWTX opened at $1.50 on Wednesday. The firm has a market cap of $50.45 million, a price-to-earnings ratio of -0.14 and a beta of 1.70. The firm’s fifty day moving average price is $1.66 and its 200 day moving average price is $2.96. Dogwood Therapeutics has a 1-year low of $1.28 and a 1-year high of $9.50.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. As a group, analysts expect that Dogwood Therapeutics will post -0.55 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 9.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Dogwood Therapeutics in a research note on Tuesday, May 19th. Weiss Ratings lowered shares of Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.